The Prognostic Role of LRIG Proteins in Endometrial Cancer
Division of Neonatology, Obstetrics and Gynecology, Department of Women’s and Children’s Health, Karolinska Institutet, 171 77 Stockholm, Sweden
Unit of Pathology, Department of Medical Biosciences, Umeå University, 901 87 Umeå, Sweden
Institute of Perinatology and Paediatrics, Almazov National Medical Research Centre, 197 341 St. Petersburg, Russia
Unit of Professional Development, Department of Clinical Sciences, Umeå University, 901 87 Umeå, Sweden
School of Medical Sciences, Faculty of Medicine and Health, Örebro University, 701 82 Örebro, Sweden
Author to whom correspondence should be addressed.
These authors contributed equally.
Academic Editors: Neville Hacker, Suzy Marie E. Scholl and Eva Colas
Received: 27 January 2021
Revised: 2 March 2021
Accepted: 10 March 2021
Published: 17 March 2021
Over the past few years, there have been many studies investigating the LRIG (leucine-rich repeats and immunoglobulin-like domains) family of transmembrane proteins, focusing mainly on their role in cancer progression. However, the prognostic role of the proteins in endometrial cancer was not studied, even though it is the most common gynecologic cancer in developed countries. Therefore, our research group aimed to fill this knowledge gap. Here, our study analyzed endometrial cancer tissue using immunohistochemistry. As a result, we found that one of the LRIG proteins—LRIG3—might influence endometrial cancer survival rates. However, the role of the LRIG1 and LRIG2 proteins in the group remains to be clarified. In conclusion, our study expands upon knowledge on the prognostic role of LRIG family in gynecological malignancies.